Systemic lupus erythematosus (SLE) patients exhibit accelerated development of
atherosclerosis and increased incidents of cardiovascular disease (CVD) that cannot be …

Objective Among traditional atherosclerotic risk factors, dyslipidemia is believed to
decisively affect the long-term prognosis of lupus patients, not only with regard to …

Systemic lupus erythematosus (SLE) is an autoimmune disease in which the immune
system attacks its own tissues and organs. However, the causes of SLE remain unknown …

Systemic lupus erythematosus (SLE) is one of the autoimmune diseases characterized by
the lack of self-tolerance and the formation of immune complexes and nuclear autoantigens …

The pharmacological treatment of systemic lupus erythematosus (SLE) aims to decrease
disease activity, progression, systemic compromise, and mortality. Among the …

Background: Dyslipidemia is a common disorder in systemic lupus erythematosus (SLE)
patients. It is still inconclusive whether antimalarial drugs could affect the serum lipids in SLE …

Objective: To determine the frequency of dyslipidemia in patients with lupus nephritis and its
association with the degree of proteinuria. Methods: This cross-sectional analytic study …

Antecedentes Los pacientes con lupus eritematoso sistémico (LES) tienen mayor frecuencia
de factores de riesgo cardiovascular (RCV) tradicionales, esto sumado a la presencia de …

Purpose Systemic lupus erythematosus (SLE) is an autoimmune disease with high mortality
and morbidity rates, one of the causes of which is cardiovascular events. Dyslipidaemia is …

Reduction in SLEDAI is associated with improved arterial sti... : Medicine Reduction in SLEDAI
is associated with improved arterial stiffness in systemic lupus erythematosus : Medicine Log in …